Grant of Share Options
Shield Therapeutics plc announced on May 5, 2026, that its Chief Executive Officer, Anders Lundstrom, was granted 5,162,294 share options under the company's Retention and Performance Share Plan. These options, representing approximately 0.48% of the total AIM securities in issue, have an exercise price of £0.079 and will vest three years from the grant date, contingent on Mr. Lundstrom remaining in his role. This grant follows Mr. Lundstrom's existing holding of 585,000 ordinary shares.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 05 May 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 04 May 2026 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group's Chief Executive Officer ("CEO").
The following options have been granted to Anders Lundstrom, CEO, who is deemed a PDMR:
| Name | Option Plan | Number of Ordinary Shares under Option | Vesting Date |
|---|---|---|---|
| Anders Lundstrom | RPSP | 5,162,294 | Three years from date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting. |
The proportion of total options awarded to Anders Lundstrom is approximately 0.48% of the total number of AIM securities in issue at this time.
Anders Lundstrom currently holds 585,000 ordinary shares in the Company.
| a) | Name | Anders Lundstrom |
| 2. | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ amendment | Initial Notification |
| 3. | Details of the Issuer | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI code | 213800G74QWY15FC3W71 |
| a) | Description of the financial instrument Identification code | Options over new Ordinary Shares ISIN: GB00BYV81293 |
| b) | Nature of the transaction | Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan. |
| c) | Price(s) and volumes(s) | 2026 RPSP Award Price (£) Volume 0.079 5,162,294 |
| d) | Aggregated information - Aggregate volume - Price | Awards granted over 5,162,294 shares in total 7.9p exercise price |
| e) | Date of the transaction | 04 May 2026 |
| f) | Place of the transaction | Outside of trading venue |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.